Oncology

Back to articles

Breast Cancer Prevention: Tamoxifen Gets Nod

KEY POINT

For women with hormone-receptor–positive breast cancer, a 5-year course of adjuvant tamoxifen remains the standard therapy, according to an evidence-based technology assessment of aromatase inhibitors approved by the Board of Directors of the American Society of Clinical Oncology (ASCO). A second ASCO technology assessment concludes that tamoxifen 20 mg/day for 5 years should be used for breast cancer risk reduction in women with a defined 5-year projected breast cancer risk of 1.66% or greater.

SOURCES

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor–positive breast cancer: status report 2002. J Clin Oncol. 2002;20:3317–27.

Chlebowski RT et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20:3328–43.